Form 4: Arcutis Biotherapeutics Director Patrick Heron Boosts Stake with $34,590 Share Purchase

Arcutis Biotherapeutics, Inc. Director Patrick J. Heron reported the acquisition of 2,646 shares of common stock at a weighted average price of $13.0803 per share, signaling increased insider confidence.

Summary

• Patrick J. Heron, a Director of Arcutis Biotherapeutics, Inc. (ARQT), acquired 2,646 shares of the company's common stock.
• The transaction occurred on June 13, 2025, at a weighted average price of $13.0803 per share.
• The shares were purchased in multiple transactions at prices ranging from $12.945 to $13.51, inclusive.
• This purchase was made pursuant to a Rule 10b5-1 pre-planned trading arrangement.
• Following this transaction, Mr. Heron directly holds 26,435 shares.
• He also indirectly holds a significant number of shares through various entities: 27,448 shares via Frazier Life Sciences X, L.P., 8,785,284 shares via Frazier Life Sciences VIII, L.P., 7 shares via FHM Life Sciences VIII, L.L.C., and 23,688 shares via The Heron Living Trust 11/30/2004.

Sentiment

Score: 8

Explanation: The purchase of shares by a director is a strong positive signal, indicating insider confidence in the company's prospects. The transaction being under a 10b5-1 plan suggests a deliberate, pre-planned investment.

Positives

• A Director, Patrick J. Heron, purchased 2,646 shares of Arcutis Biotherapeutics common stock, indicating insider confidence in the company's future prospects.
• The purchase was made at a weighted average price of $13.0803 per share, reflecting a direct investment by a key insider.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned investment strategy.

Risks

• This Form 4 filing does not detail specific risks. However, as an investment in a publicly traded company, Arcutis Biotherapeutics is subject to general market risks, industry-specific risks (biotechnology), and company-specific operational and financial risks.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The transaction involves a director of Arcutis Biotherapeutics, Inc., a company operating in the biotechnology and pharmaceutical sector. Insider purchases in this industry can be viewed as a positive signal, especially given the capital-intensive nature and regulatory hurdles often faced by biotech firms.

Comparison to Industry Standards

• This Form 4 filing reports an individual insider transaction and does not provide data for direct comparison to industry-wide financial benchmarks or specific competitor results. Insider buying, however, is generally seen as a positive indicator across all industries, suggesting management's belief in the company's undervaluation or strong future prospects.

Related Party Transactions

• Patrick J. Heron, as a managing member of the general partners of Frazier Life Sciences X, L.P., Frazier Life Sciences VIII, L.P., and FHM Life Sciences VIII, L.L.C., indirectly holds shares through these entities. He disclaims beneficial ownership except to the extent of his pecuniary interest therein.
• Shares are also held directly by The Heron Living Trust 11/30/2004, where Mr. Heron is a co-trustee with voting and investment power.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign, potentially increasing investor confidence and demand for the stock.
• The transaction reinforces the alignment of interests between management (represented by the director) and shareholders.

Next Steps

• This Form 4 filing does not outline specific future actions, events, or milestones for Arcutis Biotherapeutics, Inc.

Key Dates

Recommendation

Keywords

Arcutis Biotherapeutics, ARQT, Patrick J. Heron, Director, Insider Trading, SEC Form 4, Share Purchase, Common Stock, Biotechnology, Pharmaceutical, Insider Ownership, Rule 10b5-1